Merit Medical Opens New Facility in Galway, Ireland

Merit Medical officially opened a new $25 million facility at the Parkmore Business Park East in Galway, Ireland on May 15, 2012. Merit Chairman and CEO Fred Lampropoulos and the Prime Minister of Ireland, Enda Kenny, spoke at the opening ceremony.

Prime Minister Kenny expressed his appreciation for Merit Medical’s investment in Ireland. Lampropoulos praised the Irish workforce: “Our high level of satisfaction with our Galway facility’s ability to take on new challenges and its successful track record in developing new products over the past 16 years were major factors in implementing this crucial investment there.”

The new 75,000 square foot building will be the principal site for the development and manufacture of guide wires and inflation devices such as InQwire® Guide Wires, Merit MAK™ Mini Access Kits, and BasixCOMPAK™ Inflation Devices.

Merit Medical’s Ireland facility is responsible for providing general, financial, and operational management to its European operations. Lampropoulos believes the new facility will play a significant role in increasing the company’s global business.

Continuing conservative care versus crossover to RF-TVA (radiofrequency kyphoplasty): a comparative effectiveness study on the treatment of vertebral body fractures.

Bornemann R, Hanna M, Kabir K, Goost H, Wirtz C, Pflugmacher R. Euro Spine J 2012. Pubmed PMID: 22234722

BACKGROUND: There is controversy about how to treat vertebral fractures. Conservative care is the default approach. The aims of this study were to compare RF-TVA to conservative care and assess the usual algorithm of starting all patients on conservative care for 6 weeks before offering RF-TVA.

METHODS: Elderly patients with painful osteoporotic vertebral compression fractures were all treated with 6 weeks of conservative care (analgesics, bracing, and physiotherapy). They were then offered the choice of continuing conservative care or crossing over to radiofrequency kyphoplasty, at 6 and 12 weeks. Clinical success was defined as: (1) VAS pain improvement ≥2, (2) final VAS pain ≤5, (3) no functional worsening on ODI.

RESULTS: After the initial 6 weeks of conservative care, only 1 of 65 patients met the criteria for clinical success, and median pain VAS improvement was 0. After 12 weeks of conservative care, only 5 of 38 patients met the criteria for clinical success, and median pain VAS improvement was 1. After RF-TVA, 31 of 33 patients met the criteria for clinical success, and median pain VAS improvement was 5. Median range improvement in function ODI score was 38 (range 22-56). Cement leakage was only seen in 3 of 56 (5%) levels operated.

stabilit-bornemann-vas

stabilit-bornemann-odi

CONCLUSION: For the vast majority of patients with a VAS ≥5, conservative care did not provide meaningful clinical improvement. In contrast, nearly all patients who underwent RF-TVA had rapid substantial improvement. RF-TVA was more effective than conservative care.

Merit Medical Hosted Industry Session and “Meet the Authors” Breakfast at Global Embolization Symposium and Technologies (GEST) in New York, May 3-6, 2012

Merit Medical exhibited at GEST, the “world’s foremost meeting on embolization,” in New York, May 3-6, 2012. GEST assembled experts from around the world to discuss the latest developments in embolization therapy and treatment. The symposium included lectures, panel discussions, demonstrations, and hands-on sessions.

Merit Medical sponsored an industry session on Thursday, May 3 from 12:30 to 1:15 P.M. Speakers Maurizio Grosso, MD and Julien Namur, PhD discussed “HepaSphere™ Microspheres for HCC: Patient Outcomes and Considerations in Embolic Sizing.”

Merit Medical also hosted a “Meet the Authors” breakfast reception on Friday, May 4 from 6:45 to 7:45 A.M. with innovators and thought leaders in Interventional Radiology and Oncology including Francisco Carnevale, MD, PhD, Alberto Antunes, MD, Maurizio Grosso, MD and Julien Namur, PhD.

We enjoyed hosting these events and talking with GEST attendees about our suite of tools for embolization procedures including the Merit Maestro® Microcatheter, Tenor® Steerable Guidewire, and other products designed to enhance the practice of interventional medicine.

Merit Medical Recognized as a Diamond Sponsor of Global Embolization Symposium and Technologies (GEST) 2012

Merit Medical was recognized as a Diamond-level sponsor at GEST 2012 in New York, May 3-6. A Diamond-level sponsor designation is given to companies who contribute $100,000 or more to support the annual GEST symposium, its audiovisual services, GEST faculty, and educational materials.

Each year, GEST assembles experts from around the world to discuss the latest studies, treatment options, and clinical results using embolization for the treatment of peripheral vascular disease, aortic disease, uterine fibroids, trauma, gastrointestinal hemorrhage, vascular malformations, and liver cancers.

GEST 2012 acknowledged Merit Medical’s support in the syllabus/course book as well as on signs and display boards on site at the symposium.

Merit Medical is proud of its sponsorship, which allows the symposium to provide excellence in continuing medical education and to enhance the educational experience of attendees at the “world’s foremost meeting on embolization.”

Merit Medical Hosted Satellite Symposium on HepaSphere™ Microspheres at ECIO 2012

The Third European Conference on Interventional Oncology (ECIO) was held April 25-28 in Florence, Italy. ECIO assembles experts from around the world to discuss the latest advances in cancer imaging and treatment in satellite symposia, scientific programs, and hands-on workshops.

Merit Medical hosted a satellite symposium: “HepaSphere Microspheres for HCC: patient outcomes and considerations in embolic sizing.” Maurizio Grosso, MD presented “HepaSphere Microspheres for unresectable HCC: clinical results” and Valentin Verret, Eng, MSc presented “HepaSphere Microspheres: pre-clinical comparative data for smaller size HepaSphere Microspheres.”

We were proud to showcase HepaSphere Microspheres and the compelling advantages of drug-eluting TACE for the treatment of hepatocellular carcinoma along with our suite of tools for embolization procedures including the Merit Maestro® Microcatheter, Tenor® Steerable Guidewire, and other procedural products.

Merit Medical Releases Interactive App for the EN Snare® Endovascular Snare System

I am pleased to announce the availability of a new interactive app for the EN Snare Endovascular Snare System. This app is designed to help customers when selecting the appropriate EN Snare configuration for use in a desired vein or artery. The app is also designed to provide the EN Snare product codes and technical specifications for reference and ordering purposes.

Interested in downloading the EN Snare Endovascular Snare System interactive app? You can access it via the following web link:

http://cloud.merit.com/apps/ensnare/index.html

To add this interactive app to your iPad, open the link within Safari and select the menu option “Add to Home Screen.” Once complete, close Safari and access the app directly by tapping on the EN Snare app icon.

Jesse Hansen
Senior Product Manager, Merit Medical